Silver Book Fact

A prostate cancer vaccine, sipleucel-T immunotherapy, in men with metastatic castration-resistant prostate
cancer, reduced the risk of death by 22 percent compared to placebo, and represented a 4.2 month improvement in median survival.

Kantoff P, Higano C, Shore N, Berger E, et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. NEJM. 2010; 363: 411-22. http://www.nejm.org/doi/full/10.1056/NEJMoa1001294

Reference

Title
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Publication
NEJM
Publication Date
2010
Authors
Kantoff P, Higano C, Shore N, Berger E, et al.
Pages
411-22
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • An experimental drug may help those women whose breast cancer worsens despite use of other therapies. The medicine was shown in studies to nearly double the time breast cancer…  
  • A modest decrease of 1% in cancer mortality has been estimated to be worth $500 billion in social value.  
  • Intensity modulated radiation therapy (IMRT) precisely maps and targets tumors with better tumor control and fewer side effects than other forms of radiation. In one study, IMRT increased the success…  
  • Cancer mortality declined more than 2% in 2003, a continuation of the decline that began in 1990.  
  • Reductions in mortality for lung, female breast, prostate, and colorectal cancers accounted for 60 to 80 percent of the total decrease in all cancer deaths since the early 1990s.